Generics Versus Brands: New Fronts on a Shifting Battleground


The long-running conflict between brand-name and generic drug manufacturers always has been hard-fought—but there are signs it could become even more intense. With the Obama administration's effort to severely hamper "pay-for-delay" settlement agreements between generic and brand name drugs, and the increasingly aggressive tactics by both sides in areas such as carve-outs, at risk launches, and extended-release drugs, the industry can expect to find the two sides fighting harder than ever.

On some fronts, generics makers may have the advantage; on others, the innovators may have the better odds. But for both, the outcome of several in-progress skirmishes could be more uncertainty, more disruption, and more expense.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.